The North America Vascular Access Device Market was valued at $2524.9 Million in 2026 and projected to reach to $3487.6 Million by 2031, representing a compound annual growth rate of 6.7%. North America's vascular access device market is poised for steady growth driven by an aging population, rising prevalence of chronic diseases, and continuous technological innovations in device design and materials.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America's vascular access device market is valued at $2,524.9 million in 2026 and is projected to reach $3,487.6 million by 2031, representing a robust 6.7% CAGR aligned with global growth rates.
North America benefits from state-of-the-art medical facilities, high adoption of innovative technologies, and well-established clinical protocols that drive demand for premium vascular access solutions.
The region experiences significant prevalence of chronic kidney disease, cancer, and other conditions requiring dialysis and chemotherapy, creating sustained demand for reliable vascular access devices.
Comprehensive insurance coverage and favorable reimbursement policies in the US and Canada support market expansion and enable healthcare providers to invest in advanced vascular access technologies.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SUBCUTANEOUS (Route Of Insertion) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 6.7% from 2026 to 2031 |
| Largest Segment | INTRAVENOUS (Route Of Insertion) |
| Market Size Base Year (Billions) | ~USD 6.29 (2026) |
| Revenue Forecast (Billions) | ~USD 8.7 (2031) |
| Segments Covered | Type, Route Of Insertion, Application, End User |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PENUMBRA, INC. | United States | Public Company | Neurovascular thrombectomy (Penumbra System, RED, JET, ACE, ENGINE, 3D Revascularization Device),Peripheral thrombectomy (Indigo, Lightning Flash, Lightning Bolt 7, CAT RX),Neuro and peripheral embolization (Ruby platforms, POD, coils, LANTERN, Packing Coil), |
| SANOFI | France | Public Company | Pediatric and Combination Vaccines (including hexavalent),Other Vaccines (RSV, travel, rabies, yellow fever, typhoid, hepatitis A),Immunology & Inflammation Therapies, |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, IV and vascular access, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics, hemodynamic monitoring),BioPharma Systems (prefillable drug delivery systems and related services), |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| TELEFLEX INCORPORATED | United States | Public Company | Vascular access and emergency medicine (Arrow, EZ-IO, QuikClot, FAST1),Surgical products (Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, Titan SGS),Interventional cardiology and peripheral (GuideLiner, Turnpike, TrapLiner, MANTA, DCBs, stents, balloons), |
| ICU MEDICAL INC. | United States | Public Company | IV solutions and diluents,Infusion pumps and hardware,Vascular access and needlefree connectors, |
| MERIT MEDICAL SYSTEMS | United States | Public Company | Cardiovascular – Peripheral Intervention (angiography, drainage, delivery, embolotherapy),Cardiovascular – Cardiac Intervention (access, EP/CRM, fluid management, hemodynamic, hemostasis),Oncology and Spine (soft tissue biopsy, vertebral augmentation, RFA, bone biopsy), |
| NIPRO CORPORATION | Japan | Public Company | Renal care (hemodialysis machines, dialyzers, blood tubing sets),Injection and infusion (syringes, catheters, IV sets),Glass pharma packaging and components, |
| ANGIODYNAMICS | United States | Public Company | Med Tech (Auryon, AlphaVac, AngioVac, NanoKnife, Solero, VenaCure EVLT),Med Device (peripheral catheters, guidewires, ports, drainage, micropuncture kits), |
| AMECATH | Egypt | Private Company | Dialysis catheters,Central venous and midline catheters,Urology catheters, |
PENUMBRA, INC. is a United States-based public company founded in 2004 with 4700 employees.
SANOFI is a French public company founded in 1994 with 74846 employees.
BECTON, DICKINSON AND COMPANY is a United States-based public company founded in 1897 with 72000 employees.
TERUMO CORPORATION is a Japanese public company founded in 1921 with 30591 employees.
TELEFLEX INCORPORATED is a United States-based public company founded in 1943 with 15500 employees.
ICU MEDICAL INC. is a United States-based public company founded in 1984 with 13000 employees.
MERIT MEDICAL SYSTEMS is a United States-based public company founded in 1987 with 7500 employees.
NIPRO CORPORATION is a Japanese public company founded in 1954.
ANGIODYNAMICS is a United States-based public company founded in 1988 with 632 employees.
AMECATH is an Egypt-based private company founded in 1991.
| Country | 2025 size (native) |
|---|---|
| US | USD 1687.7 Million |
| Canada | USD 183.7 Million |
North America's vascular access device market is projected to reach $3,487.6 million by 2031, up from $2,524.9 million in 2026.
North America's vascular access device market is expected to grow at a compound annual growth rate of 6.7% between 2026 and 2031.
North America's market growth is driven by an aging population, increasing prevalence of end-stage renal disease, advanced healthcare infrastructure, strong reimbursement frameworks, and adoption of innovative technologies.
North America is a mature, high-value market with established healthcare systems, strong regulatory standards, and significant investment in medical device innovation, positioning it as a key growth region globally.
North America shows strong demand for arteriovenous fistulas, grafts, and central venous catheters, driven by dialysis and oncology applications requiring reliable long-term vascular access.
Secondary research was conducted to gather information for this technical, market-oriented, and commercial study of the global vascular access device (VAD) market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Different approaches, such as top-down and bottom-up, were used to estimate the total market size. After that, market breakup and data triangulation procedures were used to estimate the size of the segments and subsegments of the VAD market.
In the secondary research process, various secondary sources were consulted to identify and collect information for the study. These sources included annual reports, press releases, and investor presentations of device manufacturers; regulatory filings and clearance databases; clinical literature and peer-reviewed journals; healthcare and infection-control association publications; certified publications; and white papers. Secondary research was primarily used to obtain key information on the industry's supply chain, the total pool of key players, market classification and segmentation according to industry trends down to the most granular level, regional markets, and key developments from both market- and technology-oriented perspectives. All of this information was further validated by primary sources.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report: marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the vascular access device market. Primary sources on the demand side include directors and presidents of hospitals & cardiac centers, as well as scientists/researchers from academic & research institutes. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends and dynamics.
In the market engineering process, top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted throughout the market engineering process to present key information and insights throughout the report.
After the complete market engineering process—including calculations for market statistics, market breakups, market size estimates, market forecasts, and data triangulation—extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also used to identify segmentation types, industry trends, the competitive landscape among VAD market players, and key market dynamics, including drivers, restraints, opportunities, challenges, and key strategies.

Note 2: Tier 1 companies – revenue higher than USD 10 billion; Tier 2 companies – revenue between USD 1 and 10 billion; Tier 3 companies – revenue between USD 500 million and USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Top-down and bottom-up approaches were used to estimate and validate the size of the VAD market and the sizes of various dependent subsegments within the overall market. The research methodology used to estimate market size included identifying key market players through secondary research and determining their market shares in each region through both primary and secondary research. This entire procedure included the study of the annual and financial reports of the top market players, and extensive interviews were conducted with key industry leaders, such as CEOs, VPs, directors, and marketing executives, to gain key insights.
All percentage splits and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the market covered in this research study have been accounted for, examined in extensive detail, verified through primary research, and analyzed to obtain the final quantitative and qualitative data. This data is consolidated and combined with detailed input and analysis from MarketsandMarkets.

After determining the overall market size using the market size estimation processes explained above, the market was segmented into several segments and subsegments. Data triangulation and market breakup procedures were employed, where applicable, to complete the overall market engineering process and obtain the exact statistics for each market segment and subsegment. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
A vascular access device (VAD) is a medical device used to gain access to a patient's bloodstream for the administration of drugs, fluids, blood products, and nutrition, as well as for blood sampling and diagnostic procedures. VADs include peripheral devices (such as peripheral intravenous catheters, midline catheters, and arterial catheters), central devices (such as peripherally inserted central catheters, centrally and non-tunneled/tunneled central venous catheters, and implantable ports), and intraosseous access systems, along with related accessories. These devices incorporate features such as safety-engineered designs, antimicrobial and antithrombogenic coatings, and compatibility with ultrasound-guided insertion to ensure safe, reliable, and repeatable vascular access across hospital, ambulatory, and home-care settings.
With the provided market data, MarketsandMarkets offers customizations tailored to company-specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Vascular Access Device Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report